Your neurologist prescribed Emgality because it’s the right preventive treatment for your migraines. Your health insurer decided otherwise. But an insurance denial isn’t the end of the conversation, and you have legal rights that most patients never exercise.

Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) monoclonal antibody, one of a class of injectable therapies specifically designed to prevent migraine attacks before they start. Unlike older preventive medications that were originally developed for other conditions and repurposed for migraines, Emgality was built from the ground up to target the CGRP pathway, a biological mechanism central to how migraines work. It received FDA approval in September 2018 for preventive treatment of migraine in adults and is also approved for episodic cluster headache.

Despite strong clinical evidence and more than 90% of commercial health plans including Emgality coverage on their formularies, actually getting that coverage activated is a different story. Most plans require prior authorization, and the majority demand that you try and fail two or more older preventive medications before they’ll approve a CGRP drug like Emgality. If you’re reading this, you’ve likely already hit that wall.

Here’s the reality insurance companies don’t advertise: fewer than 1% of denied claims are ever appealed. When patients do appeal with the right evidence, the results are dramatically different. At Claimable, over 80% of our appeals succeed in established conditions.

This guide explains exactly why Emgality gets denied, what makes these denials often medically unjustifiable, and how to build an appeal that wins, including the clinical arguments, documentation strategies, and legal protections that actually change outcomes.

Why Insurance Companies Deny Emgality Coverage

Before you do anything else, find the specific reason your insurer denied your prescription. The denial reason determines your entire appeal strategy, and using the wrong argument wastes time you don’t have.

The Step Therapy Problem: Months of Medication Roulette Before You Get What Actually Works

Most Emgality denials come down to one thing: step therapy. Your health insurer requires you to try and fail older, cheaper standard preventatives before they’ll approve a migraine-specific CGRP inhibitor, even when the leading medical society in headache medicine says that requirement is no longer clinically justified.

The medications insurers typically demand you try first weren’t designed for migraines at all. They’re repurposed therapies from other fields: beta-blockers originally developed for blood pressure and heart conditions (propranolol, metoprolol), antidepressants (amitriptyline, venlafaxine), and antiepileptic drugs (topiramate, valproate). Some of these drugs do help some patients, but the side effect profiles are significant, and the dropout rates tell the real story.

Consider topiramate, one of the most commonly required step therapy medications. In clinical trials for migraine prevention, approximately 25% of patients on the standard 100mg dose discontinued treatment due to adverse events. The most common reasons: paresthesia (tingling and numbness), fatigue, and difficulty with concentration and memory. These side effects are severe enough that patients often call topiramate “Dopamax” for its cognitive effects. Beta-blockers can cause fatigue, depression, and exercise intolerance. Antidepressants carry their own constellation of side effects including weight gain, dry mouth, and sedation.

Insurers know all of this. Step therapy isn’t a medical strategy. It’s a cost strategy. The older drugs are cheaper, and the insurer saves money for every month you spend trying medications that may not work and may make you feel worse.

The American Headache Society’s 2024 position statement directly challenges this approach. After reviewing more than a decade of clinical evidence and real-world experience, the AHS now recommends that CGRP inhibitors, including Emgality, should be considered a first-line option for effective migraine prevention, without requiring prior failure of other drug classes. The statement is unequivocal: the cumulative evidence for efficacy, safety, and tolerability of CGRP therapies is significantly greater than that for any established migraine preventive treatment.

When your insurer requires you to spend months cycling through medications with high discontinuation rates and substantial side effects before approving Emgality, they’re overriding the judgment of both your prescribing neurologist and the nation’s leading headache specialists.

The Most Common Emgality Denial Types

Step Therapy Required

This is the most common reason Emgality injections are denied. Insurers including Aetna, Anthem Blue Cross, Cigna, UnitedHealthcare, Blue Shield, and Humana all typically require documented failure of at least two classes of preventive medications before approving CGRP drugs. The specific requirements vary by plan, but the pattern is consistent: try the cheap options first, even if your doctor has already determined they’re not right for you.

“Failure” is defined more broadly than most patients realize, and that’s where your appeal leverage lives. You don’t need to prove a medication was completely useless. Any of the following counts: the drug didn’t reduce your migraine frequency enough, side effects or intolerances made the drug unbearable, you have a medical condition that contraindicates the drug (cardiovascular disease for beta-blockers, kidney stones for topiramate, pregnancy planning for valproate), or you had to discontinue for any documented medical reason. Prior medication trials from other doctors or previous insurers also count. You shouldn’t have to restart the failure clock every time your coverage changes.

Important: The AHS 2024 position statement specifically states that initiation of CGRP-targeting therapies should not require trial and failure of non-specific migraine preventive medication approaches. This is your strongest clinical argument in any step therapy appeal.

Not Medically Necessary

A medical necessity denial usually means the initial submission didn’t include enough clinical detail, not that your insurer made a careful medical judgment. Common documentation gaps for Emgality include: not specifying the number of migraine days per month, not providing a complete treatment history with specific drug names, dosages, durations, and outcomes, not documenting how migraines impact your ability to work and function, or not explaining why Emgality specifically is the right choice.

For Emgality, your prescriber’s documentation should establish your migraine diagnosis with the correct ICD-10 code, quantify your migraine burden (frequency, severity, and disability), list every prior preventive medication tried with specific reasons each was inadequate, and articulate the clinical rationale for choosing a CGRP monoclonal antibody.

Not on Formulary / Non-Preferred Brand

Some health insurance plans prefer a different injectable CGRP medication, often Aimovig (erenumab), Ajovy (fremanezumab), or Vyepti (eptinezumab), over Emgality. This is typically a pricing decision, not a clinical one. All four injectable CGRP drugs are effective preventive therapies, but they’re not interchangeable for every patient.

This matters for your appeal: Emgality and Ajovy work by binding the CGRP ligand (the protein itself), while Aimovig targets the CGRP receptor. These are meaningfully different mechanisms, and patients who don’t respond to one may respond well to another. If your insurer is asking you to switch to a preferred alternative, and you’ve already tried that medication without adequate results or your neurologist has a specific clinical reason for choosing Emgality, that’s a strong basis for a formulary exception.

The CONQUER trial specifically demonstrated that Emgality is effective in patients who have failed two to four prior preventive medication categories, meaning it has published evidence of working in exactly the population most likely to face insurance barriers.

Frequency Threshold Not Met

Most insurers require a minimum of 4 migraine days per month to qualify for Emgality coverage. If your denial cites this reason, it often means the documentation didn’t clearly establish your migraine frequency, not that you don’t actually meet the threshold. A detailed headache diary showing your true migraine burden, corroborated by your neurologist’s clinical assessment, is typically what’s needed to address this.

Keep in mind that many patients underreport migraine frequency in routine visits. If you experience 4 or more migraine days per month (the standard clinical threshold for considering preventive treatment), make sure that number is explicitly documented in your medical records.

Incorrect Diagnosis Code

Emgality coverage requires specific ICD-10 migraine diagnosis codes. Common codes that support Emgality prescriptions include: migraine without aura (G43.00, G43.01), migraine with aura (G43.10, G43.11), chronic migraine without aura (G43.709, G43.711), and migraine, unspecified (G43.90, G43.91). Using a general headache code like R51.9 (“headache, unspecified”) will almost certainly trigger a denial.

If your denial stems from a coding issue, this is often the simplest fix. Work with your prescriber’s office to verify and correct the submitted diagnosis code.

Prior Authorization Expired

Emgality typically requires reauthorization every 6 to 12 months. If your PA has lapsed, you’ll need to resubmit with updated documentation showing that the medication is still working, ideally including migraine diary data demonstrating continued response (a 50% or greater reduction in monthly migraine days is the standard clinical benchmark). Start the renewal process 30 to 45 days before your current authorization expires to avoid gaps in treatment.

How to Appeal an Emgality Denial: Step by Step

A denial is not a final answer. It’s the beginning of a process that patients are legally entitled to, and that works far more often than the insurance industry would like you to believe.

Step 1: Read Your Denial Letter Carefully

Your denial letter must include the specific reason for the denial, your appeal rights, and the deadline to file. Find the deadline immediately. Most commercial plans allow 180 days, but some insurers set shorter windows. UnitedHealthcare allows 65 days. Medicare Advantage plans follow CMS guidelines of 60 days. Missing your deadline forfeits your right to appeal.

Step 2: Understand That You Can Appeal Independently

You can file a patient-initiated appeal separate from anything your doctor’s office submits. This isn’t just a backup. Patient appeals carry their own legal protections under the ACA, including mandated response timelines, the right to escalate to an independent external reviewer, and multiple levels of appeal. If your neurologist’s prior authorization was denied, your path is still open.

Step 3: Verify Clinical Details With Your Prescriber

Before building your appeal, confirm with your doctor’s office: Is your migraine frequency clearly documented? Are all prior preventive medication trials listed with specific drugs, dosages, durations, and reasons for discontinuation? Is the correct ICD-10 diagnosis code on file? Was the Emgality prescription written for the correct loading and maintenance dose? If the denial stems from a documentation gap, a corrected PA resubmission may resolve it without a formal appeal.

Step 4: Get a Letter of Medical Necessity

This is the most important document in your appeal. For Emgality, a strong letter of medical necessity from your prescribing neurologist or headache specialist should include your migraine diagnosis and monthly frequency, a detailed history of every prior preventive medication tried (names, doses, duration of each trial, and specific reason each was discontinued, whether for side effects, lack of efficacy, or contraindications), how migraines affect your ability to work, care for your family, and function in daily life, and the clinical rationale for choosing Emgality, including references to the AHS guidelines supporting CGRP therapies as first-line prevention.

How to ask: “My insurance denied Emgality. Would you write a letter of medical necessity for my appeal? I can bring a list of every preventive I’ve tried and what happened with each one.” Specificity wins appeals. Vague statements like “patient failed prior therapies” are far less effective than naming the exact drugs, doses, and outcomes. If your primary care provider submitted the original prescription, consider asking a neurologist or headache specialist to write the appeal letter. Clinicians with specialized headache expertise carry additional weight with insurance medical directors.

Step 5: Build Your Appeal Package

A complete appeal should include a cover letter summarizing your case, the letter of medical necessity from your prescriber, supporting clinical documentation (office notes, headache diary data, treatment history), and a personal statement about how the denial affects your health and life.

The three pillars of a winning appeal:

Your story — How migraines disrupt your daily life. Missed work days, canceled plans, emergency room visits, the toll on your family. This isn’t supplemental. It provides the human weight that clinical data alone can’t communicate.

Clinical evidence — Peer-reviewed studies including the EVOLVE-1 and EVOLVE-2 trial results showing significant reductions in monthly migraine days vs. placebo, the AHS 2024 position statement supporting CGRP therapies as first-line, and any published evidence specific to your situation (the CONQUER trial is especially relevant if you’ve failed multiple prior preventives).

Policy and legal analysis — How your situation meets your plan’s own coverage criteria, applicable state laws, and federal protections under the ACA for appeals and external review.

Step 6: Submit and Track

Follow your denial letter’s submission instructions precisely. Your insurer must respond within 30 days for standard appeals or 72 hours for an expedited appeal (also called an urgent appeal; request this if a delay in treatment could seriously harm your health). Keep records of everything: submission date, method (fax, mail, portal), and all confirmation numbers.

Step 7: Escalate If Needed

If your internal appeal is denied, you have the right to an external review by an independent third party who doesn’t work for your health insurer. External reviewers evaluate medical justification, not the insurer’s financial preferences. These reviews overturn denials more often than most patients expect, because the standard shifts from the insurer’s internal criteria to independent clinical judgment.

The system is designed to wear you down. Persistence is part of the strategy.

An Easier Path: Let Claimable Handle Your Emgality Appeal

If building an appeal from scratch isn’t realistic, or if you’ve already been denied and don’t have the bandwidth for another round, Claimable can handle it for you.

Here’s how it works:

Answer a few questions about your Emgality denial and medical history. We build your case using our database of 4+ million clinical studies, insurer policies, and legal standards. We create a fully customized appeal with your personal story, clinical evidence, and policy analysis. We submit it for you, faxed and mailed directly to your insurer. We guide you through escalation if needed.

Over 80% of Claimable appeals succeed, with most resolved in 10 days or less.

“When my insurance company denied my claim to continue with my medicine, I felt defeated at first… Then I found Claimable. In the end I ended up winning my claim and I couldn’t have done it without Claimable. I highly recommend them.” — April A.

Appealing with Claimable costs $39.95. No success fees, no hidden costs, just a flat fee. When Emgality runs $700 to $970 per month without insurance coverage, the math is straightforward.

Start your Emgality appeal →

Appeal Timelines: How Long Does an Emgality Appeal Take?

A complete, well-documented appeal submitted from the start is the fastest path to a decision. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Emgality denied if my plan covers it?

Having Emgality on your plan’s formulary doesn’t guarantee automatic approval. Most plans require prior authorization, and those PA criteria typically include step therapy (proof that you’ve tried and failed older preventive medications), minimum migraine frequency thresholds, and specific documentation requirements. Your plan may technically cover Emgality, but “covered” and “approved without a fight” are very different things.

Do I really have to try older medications like topiramate before getting Emgality?

That depends on your insurer’s current policies, but you may not need to start from scratch. If you’ve previously tried and discontinued standard preventatives for any documented medical reason (side effects, intolerances, lack of efficacy, or contraindications) those prior trials should satisfy step therapy requirements. And if your healthcare provider can cite the AHS 2024 position statement recommending CGRP inhibitors as first-line, that strengthens the argument that step therapy shouldn’t apply to your case at all.

Can I appeal an Emgality denial myself, or does my doctor have to do it?

You can appeal yourself. Patient-initiated appeals carry their own legal protections: mandated timelines, the right to external review, and multiple appeal levels. Your appeal is independent of anything your doctor files. Both can proceed simultaneously.

What’s the difference between Emgality and other CGRP injections like Aimovig?

All four injectable CGRP drugs, Emgality, Aimovig (erenumab), Ajovy (fremanezumab), and Vyepti (eptinezumab), are effective preventive therapies for migraines, but they work through slightly different mechanisms. Emgality and Ajovy target the CGRP protein itself (the ligand), while Aimovig blocks the CGRP receptor. Oral CGRP options also exist: Qulipta (atogepant) for prevention and Nurtec (rimegepant) for both prevention and acute treatment. But the injectable monoclonal antibodies offer a different pharmacological approach with once-monthly dosing. The key point: patients who don’t respond adequately to one CGRP medication may respond well to another. Failing on one doesn’t mean the entire class won’t work for you. Your doctor chose Emgality for a reason specific to your clinical situation.

How does the Emgality injection work?

Emgality is a once-monthly injection that you self-administer at home using a prefilled pen or syringe. The first dose is a loading dose of 240mg (two 120mg injections), followed by 120mg once monthly. In clinical trials, patients treated with Emgality experienced approximately 4.7 fewer migraine headache days per month compared to 2.8 fewer days with placebo, with 50% responder rates of approximately 60% over 6 months of treatment. That means about 6 in 10 patients saw their migraine days cut in half or more.

How much does Emgality cost without insurance?

Without insurance or discounts, Emgality costs approximately $700 to $970 per month for the maintenance dose (one 120mg prefilled pen). The first month’s loading dose requires two pens, roughly doubling the initial cost. Eli Lilly offers the Emgality Savings Card for commercially insured patients, which can reduce the monthly cost to as little as $35 (up to $4,900 in annual savings). Patients without commercial insurance may qualify for the Lilly Cares Foundation Patient Assistance Program, which provides Emgality at no cost to qualifying individuals. Note that neither the savings card nor the patient assistance program is available to patients enrolled in Medicare, Medicaid, or other government-funded programs, but Medicaid plans in many states do cover Emgality with copays as low as $4 to $9 per month.

What if my insurer wants me to switch to a different CGRP medication?

If your plan prefers Aimovig, Ajovy, or Vyepti over Emgality, your appeal should explain why your neurologist specifically chose Emgality. Strong grounds for a formulary exception include: you’ve previously tried the preferred alternative without adequate results, the preferred drug is contraindicated for you, or there’s a specific clinical rationale (such as Emgality’s mechanism of targeting the CGRP ligand vs. the receptor). The CONQUER trial demonstrated Emgality’s efficacy specifically in patients who had failed multiple prior preventive categories, evidence that strengthens your case if you’ve been through this before.

Is it worth appealing an Emgality denial?

Yes. The insurance industry relies on patients accepting denials without challenge. Fewer than 1% ever appeal. But denials are frequently the result of incomplete documentation, misapplied criteria, or step therapy requirements that contradict current medical guidelines. Your neurologist prescribed Emgality because your migraines are serious enough to warrant targeted preventive treatment. The appeal is your chance to make that case with the right evidence and legal framework behind you.

Claimable’s physician-led team has helped patients recover millions in care access by fighting insurance denials. We’re SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Related: Insurance Denied Ubrelvy? How to Appeal and Get Covered

Related: Insurance Denied Nurtec? Here’s What to Do